Roche's Avastin up for another lift with fast-track cervical cancer review

Roche's ($RHHBY) cancer blockbuster Avastin has yet another shot at boosting sales. The FDA put Avastin up for priority review in cervical cancer, with a decision date of Oct. 24. Already roaring ahead on new colorectal and ovarian cancer approvals, the drug could tap another big market if it wins the new indication. Report